XORTX Therapeutics Files 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Apr 21, 2026 · CIK: 0001729214
Sentiment: neutral
Topics: filing, foreign-issuer, report
TL;DR
XORTX files 6-K, check exh_991.htm for details.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is Suite 2400 - 745 Thurlow Street, Vancouver, A1 V6E 0C5.
Why It Matters
This filing provides an update from XORTX Therapeutics Inc., a foreign issuer, which may contain important operational or strategic information for investors.
Risk Assessment
Risk Level: low — A 6-K filing is typically an informational report and does not inherently signal high risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Filer
- 0001729214 (company) — CIK
- 2026-04-21 (date) — Filing Date
- EX-99.1 (document) — Exhibit
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer required under Rules 13a-16 and 15d-16 of the Securities Exchange Act of 1934.
When was this Form 6-K filed and accepted by the SEC?
The filing date and acceptance date for this Form 6-K was April 21, 2026.
What is the CIK number for XORTX Therapeutics Inc.?
The CIK number for XORTX Therapeutics Inc. is 0001729214.
What is included as an exhibit in this filing?
Exhibit 99.1, a press release, is included in this filing.
What is the business address of XORTX Therapeutics Inc.?
The business address is SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 21, 2026 regarding XORTX Therapeutics Inc. (XRTX).